Sodelglitazar
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| ATC code | None |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | 447406-78-2 |
| PubChem (CID) | 9805950 |
| ChemSpider | 7981710 |
| UNII | 6G973E04VI |
| KEGG | D06647 |
| ChEMBL | CHEMBL2104984 |
| Chemical and physical data | |
| Formula | C23H21F4NO3S2 |
| Molar mass | 499.54 g·mol−1 |
| 3D model (Jmol) | Interactive image |
| |
| |
Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline.[2] While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.[3]
Safety
Phase 2 studies were terminated prior to completion due to safety findings in rodent studies.[4]
See also
References
- ↑ US Patent No. 7105551 "96 dpi image of original patent USPTO 7105551" (PDF). Retrieved 2 Apr 2013.
- ↑ Liu, X. Y.; Wang, R. L.; Xu, W. R.; Tang, L. D.; Wang, S. Q.; Chou, K. C. (2011). "Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar". Protein and peptide letters. 18 (10): 1021–1027. doi:10.2174/092986611796378701. PMID 21592078.
- ↑ Eckhard Ottow, Hilmar Weinmann (2008). Nuclear Receptors as Drug Targets. Wiley. pp. 380–. ISBN 978-3-527-31872-8. Retrieved 2 April 2013.
- ↑ "A randomised,double-blind, parallel group, placebo-controlled, multicentre study to evaluate the safety, tolerability and efficacy of oral GW677954 capsules 2.5mg, 5mg, 10mg and 20mg a day for 24 weeks in overweight dyslipidaemic subjects" (PDF). GlaxoSmithKline. 2013-09-01.
This article is issued from Wikipedia - version of the 11/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.